Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Core Viewpoint - Connect Biopharma has regained compliance with Nasdaq's minimum bid price requirement, allowing its American Depositary Shares to continue trading on the exchange [1][2]. Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD) [3]. - The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, and is conducting global clinical studies for its treatment of acute exacerbations of asthma and COPD [3]. - Connect Biopharma has an exclusive license and collaboration agreement for rademikibart with Simcere in China [3].